

## **DIASORIN STRENGTHENS ITS LEADERSHIP OF IMMUNO DIVISION WITH THE APPOINTMENT OF GABRIELE ALLEGRI AS PRESIDENT**

**Saluggia, May 4, 2026** - Diasorin (FTSE MIB: DIA) announces the appointment of **Gabriele Allegri** as **President of the Immunodiagnostic Division**.

Gabriele Allegri brings to Diasorin over twenty years of international experience in leadership roles in the Pharmaceuticals, Diagnostics, and MedTech sectors, with proven ability in leading global commercial organizations in North America, EMEA, and Asia. Before joining Diasorin, he was Vice President, Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine in North America, where he led global commercial strategies for precision medicine and companion diagnostics. He served as Chair of the Precision Cancer Consortium (PCC) and was a Board member of the Precision Medicine Coalition (PMC), actively contributing to the development of the global precision medicine agenda.

Throughout his career, he has played a pivotal role in the development and scaling of global precision medicine strategies, with particular focus on companion diagnostics, biomarker-driven therapies, and integrated go-to-market models covering the entire diagnostic-therapeutic continuum.

*"We are delighted to welcome Gabriele to Diasorin," commented Carlo Rosa, CEO of Diasorin Group. "His deep experience in precision medicine and his commitment to diagnostic stewardship are fully aligned with our vision for the evolution of the Immunodiagnostic Division. Gabriele will bring distinctive capabilities in the responsible and data-driven use of diagnostics, with the aim of improving patient outcomes and supporting the sustainability of healthcare systems, key pillars of our long-term growth strategy."*

### **About Diasorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 9 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at [www.diasorin.com](http://www.diasorin.com)

### **FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

#### **INVESTOR RELATIONS**

##### **Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.com](mailto:riccardo.fava@diasorin.com)

##### **Eugenia Ragazzo**

Corporate Investor Relations & ESG Senior Analyst  
[eugenia.ragazzo@diasorin.com](mailto:eugenia.ragazzo@diasorin.com)